The active chemical substance in Acomplia, rimonabant, is a cannabinoid receptor antagonist (CB1). Being chemical, it usually acts within a short time after intake and stays for a limited duration. Hence, a daily supply of the drug is needed for a year-long to get its weight loss effect. This long duration of intake could be the reason behind the few cases of suicidal attempts. The site of action of Accomplia is mainly on the hippocampus, which controls the food addiction.

The Luqaimat Training Technique (LTT) innovated by me in 2005 (referenced for in my previous opinions in Medical News Today in 13, 18, 19, & 22 July 2007) acts on the same brain site but with a different mode of action that is psychobiological induction of hippocampul neuroplasticity. A few weeks is needed to the auditory visual and psychological cues to get the maximum effective.

On a relevant topic, a research was done at the University of Pennsylvania, School of Medicine published in Nov 2005 on the combining effect of Meridia and weight loss counseling sessions cited that the results of the combo was better than the summation of the two methods if applied separately.

Similarly, I think that if we put the advantage of the fast effect of Accomplia at the beginning of the weight loss program together with the advantage of the gradual effect of LTT, which appears after few weeks, we will gain a synergistic effect on hippocampul neurplasticity. This combo diet will be a great progress in the field of managing extreme obesity.

Instead of disapproving the Accomplia as a long-term weight loss drug due to its depressive effect, we can use it for initiation of controlling hunger feeling at the hippocampul level for a short-term period (e.g. 3 weeks) to be accompanied by Luqaimat Training Technique for a long-term period.